Pacira BioSciences Inc (82P.MU)
- GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the notes an option to purchase, for
- Zacks
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
- Insider Monkey
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript May 7, 2024 Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.62 EPS, expectations were $0.64. PCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]
